Trial reportFrontiers in immunology2019
Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Trial report in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Yellow Fever Vaccine Booster Trial in Children- a Phase 3 Clinical Trial to Establish Safety and Immunogenicity of Repeated YF Vaccination in Healthy Gambian Children of Different Ages
Estudio Sobre Respuesta de Anticuerpos Neutralizantes Contra la Fiebre Amarilla Cuatro a Siete años después de Vacunar Una población pediátrica Entre Los 12 y 23 Meses de Edad en Argentina
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- Immunogenicity of a single dose of the 17DD yellow fever vaccine in a cohort of adults and children in a non-endemic area, and its association with dengue and Zika seropositivity.PLoS neglected tropical diseases · 2025Trial
- Yellow Fever Vaccination in an Individual with Confirmed Egg Protein Allergy: A Case Report.Vaccines · 2026Article
- A cohort study of the duration of immunity to yellow fever after 4 years of primary vaccination in children and adults.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026Article
- Yellow fever in Latin America and the escalating risks in a changing eco-epidemiological landscape: a review.Lancet regional health. Americas · 2026Review
- Immunoprevention and immunomodulation of yellow fever: A scoping review of global and Latin American evidence.PloS one · 2026Article
- Molecular ingredients of an immunogen for long-lasting IgG.Frontiers in immunology · 2025Review
- Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.Cell reports. Medicine · 2024Article
- Off-Label Yellow Fever and Hepatitis A Vaccination in Traveling Children.Children (Basel, Switzerland) · 2024Article
- Immune response induced by standard and fractional doses of 17DD yellow fever vaccine.NPJ vaccines · 2024Article
- Booster Vaccination against Yellow Fever in Gambian children-(BoVY) -a Phase 3 clinical trial to establish safety and immunogenicity of repeated YF vaccination in healthy Gambian children of different ages.Wellcome open research · 2024Article
- Assessing yellow fever outbreak potential and implications for vaccine strategy.PLOS global public health · 2024Article
- Safe administration of yellow fever vaccine in patients with suspected egg allergy.The journal of allergy and clinical immunology. Global · 2023Article
- Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies.Cell host & microbe · 2022Article
- Article
- Chronic Myeloid Leukemia in Children: Immune Function and Vaccinations.Journal of clinical medicine · 2021Review
- Review
- Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.Current treatment options in infectious diseases · 2020Review
- Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.Current treatment options in infectious diseases · 2020Review
- Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.NPJ vaccines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Yellow Fever (YF) vaccination is recommended for people living in endemic areas and represents the most effective strategy to reduce the risk of infection. Previous studies have warned that booster regimens should be considered to guarantee the long-term persistence of 17DD-YF-specific memory components in adults living in areas with YF-virus circulation. Considering the lower seroconversion rates observed in children (9-12 months of age) as compared to adults, this study was designed in order to access the duration of immunity in single-dose vaccinated children in a 10-years cross-sectional time-span. The levels of neutralizing antibodies (PRNT) and the phenotypic/functional memory status of T and B-cells were measured at a baseline, 30-45 days, 1, 2, 4, 7, and 10 years following primary vaccination. The results revealed that a single dose induced 85% of seropositivity at 30-45 days and a progressive time-dependent decrease was observed as early as 2 years and declines toward critical values (below 60%) at time-spans of ≥4-years. Moreover, short-lived YF-specific cellular immunity, mediated by memory T and B-cells was also observed after 4-years. Predicted probability and resultant memory analysis emphasize that correlates of protection (PRNT; effector memory CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.